Aprotinin, Bovine (US/North America) (Pancreatic trypsin inhibitor)

Aprotinin inhibits the activity of several proteolytic enzymes such as chymotrypsin, kallikrein, plasmin and trypsin. It is present in blood and in most tissues, with a high concentration in lung, inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins.\nAprotinin is a natural proteinase inhibitor polypeptide consisting of 58 amino acids arranged in a single polypeptide chain, cross-linked by three disulfide bridges and having a molecular mass of 6512D.\n\nSolubility: \nColorless, clear, complete\nLoss on drying: \n(same/less than) 2.0%\nAbsorbance: \n(same/less than) 0.8\nHistamine: \n(same/less than)0.2ug/3EU\nActivity (on dried basis): \n(same/more than)5400KIU/mg\nProtein impurities of higher molecular mass: Complies\nBacterial endotooxins: None Detected\nAbnormal toxicity: Non-toxic\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with ddH2O. Aliquot and store at -20 degrees C. Reconstituted product is stable for 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

A2300-04

Size

250mg

Form

Supplied as a white powder.

References

1. Alston, T.A.: Aprotinin. Int. Anesthesiol. Clin. 42(4): 81-91 (2004). 2. Apeler, H., Peters, J., Schneider, K.H., Dembowsky, K.: Expression, purification, biochemical and pharmacological characterization of a recombinant aprotinin variant. Arzneimittelforschung 54(8): 483-97 (2004). 3. Khan T.A., Bianchi, C., Feng, J., Stahl, G.: Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J. Thorac. Cardiovasc. Surg. 128(4): 602-8 (2004). 4. Gillespie, E.L., Perkerson, K.A., Coleman, C.I.: Possible impact of aprotinin on post-cardiothoracic surgery atrial fibrillation. Conn. Med. 68(7): 439-42 (2004). 5. Levy, J.H.: Safety of aprotinin in heparinized and nonheparinized patients. J. Cardiothorac. Vasc. Anesth. 18(4 Suppl): 38S-42S (2004). 6. Porte, R.J., Hendriks, H.G.: Blood conservation in liver transplantation: The role of aprotinin. J. Cardiothorac. Vasc. Anesth. 18(4 Suppl): 31S-37S (2004).